Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome

Cancer

Volumn 118, Issue 6, 2012, Pages 1543-1553

  Kim, Geoffrey ^a   Davidson, Ben ^b,c   Henning, Ryan ^a   Wang, Junbai ^b   Yu, Minshu ^a   Annunziata, Christina ^a   Hetland, Thea ^b   Kohn, Elise C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

adhesion molecules; ascites; ovarian cancer; proteomics array

Indexed keywords

CELL ADHESION MOLECULE; EPITHELIAL CELL ADHESION MOLECULE; FOCAL ADHESION KINASE; NERVE CELL ADHESION MOLECULE; PAXILLIN; PROTEIN KINASE B; UVOMORULIN;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER CELL; CANCER EFFUSION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL ADHESION; CELL INTERACTION; CELL PROLIFERATION; DISEASE ASSOCIATION; EFFUSION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; PERITONEUM CANCER; PLEURA CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS;

ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; CELL ADHESION MOLECULES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PLEURAL EFFUSION; PROGNOSIS;

EID: 84857998326     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26449     Document Type: Article

References (51)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. Bonnefoi H, A'Hern RP, Fisher C, et al. Natural history of stage IV epithelial ovarian cancer. J Clin Oncol. 1999; 17: 767-775. (Pubitemid 29109304)
3. Davidson B,. Malignant effusions: from diagnosis to biology. Diagn Cytopathol. 2004; 31: 246-254. (Pubitemid 39314820)
4. Frisch SM, Francis H,. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994; 124: 619-626. (Pubitemid 24064472)
5. Liotta LA, Kohn E,. Anoikis: cancer and the homeless cell. Nature. 2004; 430: 973-974.
6. Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY,. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol. 1996; 134: 793-799. (Pubitemid 26269148)
7. Fouquet S, Lugo-Martinez VH, Faussat AM, et al. Early loss of E-cadherin from cell-cell contacts is involved in the onset of Anoikis in enterocytes. J Biol Chem. 2004; 279: 43061-43069. (Pubitemid 39372201)
8. Kang HG, Jenabi JM, Zhang J, et al. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res. 2007; 67: 3094-3105. (Pubitemid 46724846)
9. Maetzel D, Denzel S, Mack B, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol. 2009; 11: 162-171.
10. Patel IS, Madan P, Getsios S, Bertrand MA, MacCalman CD,. Cadherin switching in ovarian cancer progression. Int J Cancer. 2003; 106: 172-177. (Pubitemid 36835168)
11. Sivertsen S, Hadar R, Elloul S, et al. Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression. Lung Cancer. 2006; 54: 309-317. (Pubitemid 44740263)
12. Davidson B, Berner A, Nesland JM, et al. E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. J Pathol. 2000; 192: 460-469.
13. Elloul S, Silins I, Trope CG, Benshushan A, Davidson B, Reich R,. Expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Arch. 2006; 449: 520-528. (Pubitemid 44722320)
14. Elstrand M, Phuc Dong H, Odegaard E, et al. Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. Hum Pathol. 2010; 41: 794-804.
15. Davidson B, Espina V, Steinberg SM, et al. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res. 2006; 12: 791-799. (Pubitemid 43259859)
16. Sheehan KM, Calvert VS, Kay EW, et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics. 2005; 4: 346-355. (Pubitemid 40590555)
17. Annunziata CM, Walker AJ, Minasian L, et al. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin Cancer Res. 2010; 16: 664-672.
18. Winters M, Dabir B, Yu M, Kohn EC,. Constitution and quantity of lysis buffer alters outcome of reverse phase protein microarrays. Proteomics. 2007; 7: 4066-4068. (Pubitemid 350190278)
19. Carey MS, Agarwal R, Gilks B, et al. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res. 2010; 16: 2852-2860.
20. Davidson B, Risberg B, Kristensen G, et al. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers. Virchows Arch. 1999; 435: 43-49. (Pubitemid 29346741)
21. Davidson B, Nielsen S, Christensen J, et al. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol. 2001; 25: 1405-1412. (Pubitemid 33022056)
22. Rasool N, LaRochelle W, Zhong H, Ara G, Cohen J, Kohn EC,. Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells. Clin Cancer Res. 2010; 16: 600-609.
23. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J,. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009; 115: 1234-1244.
24. Curtin JP, Malik R, Venkatraman ES, Barakat RR, Hoskins WJ,. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol. 1997; 64: 9-12. (Pubitemid 27026949)
25. Akahira JI, Yoshikawa H, Shimizu Y, et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol. 2001; 81: 398-403. (Pubitemid 32494653)
26. Peng DJ, Wang J, Zhou JY, Wu GS,. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Commun. 2010; 394: 600-605.
27. Parsons JT, Slack-Davis J, Tilghman R, Roberts WG,. Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res. 2008; 14: 627-632. (Pubitemid 351231140)
28. Yap AS, Brieher WM, Gumbiner BM,. Molecular and functional analysis of cadherin-based adherens junctions. Annu Rev Cell Dev Biol. 1997; 13: 119-146. (Pubitemid 28034522)
29. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G,. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 1998; 392: 190-193. (Pubitemid 28162793)
30. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Lopes CS,. Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann Oncol. 2004; 15: 1535-1542. (Pubitemid 39409745)
31. Shim HS, Yoon BS, Cho NH,. Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma. Hum Pathol. 2009; 40: 693-698.
32. Voutilainen KA, Anttila MA, Sillanpaa SM, et al. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. J Clin Pathol. 2006; 59: 460-467.
33. Gottardi CJ, Wong E, Gumbiner BM,. E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J Cell Biol. 2001; 153: 1049-1060.
34. Elloul S, Vaksman O, Stavnes HT, Trope CG, Davidson B, Reich R,. Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions. Clin Exp Metastasis. 2010; 27: 161-172.
35. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR,. Cadherin switching. J Cell Sci. 2008; 121: 727-735. (Pubitemid 351578108)
36. Singh A, Settleman J,. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29: 4741-4751.
37. Kassis J, Klominek J, Kohn EC,. Tumor microenvironment: what can effusions teach us? Diagn Cytopathol. 2005; 33: 316-319. (Pubitemid 41598051)
38. Hudson LG, Zeineldin R, Stack MS,. Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis. 2008; 25: 643-655.
39. Sundfeldt K, Piontkewitz Y, Ivarsson K, et al. E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer. 1997; 74: 275-280. (Pubitemid 27321795)
40. Tothill RW, Tinker AV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008; 14: 5198-5208.
41. Huttenlocher A, Lakonishok M, Kinder M, et al. Integrin and cadherin synergy regulates contact inhibition of migration and motile activity. J Cell Biol. 1998; 141: 515-526. (Pubitemid 28237098)
42. Yano H, Mazaki Y, Kurokawa K, Hanks SK, Matsuda M, Sabe H,. Roles played by a subset of integrin signaling molecules in cadherin-based cell-cell adhesion. J Cell Biol. 2004; 166: 283-295. (Pubitemid 38988780)
43. Hofmann C, Obermeier F, Artinger M, et al. Cell-cell contacts prevent anoikis in primary human colonic epithelial cells. Gastroenterology. 2007; 132: 587-600. (Pubitemid 46274657)
44. Wu C, Cipollone J, Maines-Bandiera S, et al. The morphogenic function of E-cadherin-mediated adherens junctions in epithelial ovarian carcinoma formation and progression. Differentiation. 2008; 76: 193-205. (Pubitemid 351197172)
45. Kajiyama H, Shibata K, Terauchi M, et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol. 2007; 31: 277-283.
46. Witta SE, Gemmill RM, Hirsch FR, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 2006; 66: 944-950. (Pubitemid 43165962)
47. Xiang W, Wimberger P, Dreier T, et al. Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells. J Cancer Res Clin Oncol. 2003; 129: 341-348. (Pubitemid 36963196)
48. Burges A, Wimberger P, Kumper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res. 2007; 13: 3899-3905. (Pubitemid 47037597)
49. Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010; 127: 2209-2221.
50. Posadas EM, Kwitkowski V, Kotz HL, et al. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer. 2007; 110: 309-317. (Pubitemid 47121890)
51. Posadas EM, Liel MS, Kwitkowski V, et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer. 2007; 109: 1323-1330. (Pubitemid 46466559)